Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma

• Paul G. Richardson,
• Thierry Facon,
• William I. Bensinger,
• Xavier Leleu,
• Frank Campana,
• Sandrine Macé,
• Marielle Chiron,
• Helgi van de Velde,
• Joseph Mikhael

Affiliations

Paul G. Richardson

Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School

Thierry Facon

Department of Haematology, Lille University Hospital

William I. Bensinger

Myeloma & Transplant Program, Swedish Cancer Institute

Xavier Leleu

Service d’Hématologie et Thérapie Cellulaire, Hôpital de La Milétrie

Frank Campana

Sanofi-Genzyme

Sandrine Macé

Sanofi R&D

Marielle Chiron

Sanofi R&D

Helgi van de Velde

Sanofi-Genzyme

Joseph Mikhael

Translational Genomics Research Institute (TGen), City of Hope Cancer Center